AGTC

Applied Genetic TechnologiesNasdaqGM:AGTC Stock Report

Market Cap

US$139.4m

7D

-3.8%

1Y

-35.8%

Updated

16 Sep, 2021

Data

Company Financials +
AGTC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AGTC Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Applied Genetic Technologies
Historical stock prices
Current Share PriceUS$3.26
52 Week HighUS$3.12
52 Week LowUS$9.67
Beta2.15
1 Month Change-6.59%
3 Month Change-26.58%
1 Year Change-35.83%
3 Year Change-25.91%
5 Year Change-63.33%
Change since IPO-77.91%

Recent News & Updates

Jul 15

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".

Shareholder Returns

AGTCUS BiotechsUS Market
7D-3.8%-1.0%-0.6%
1Y-35.8%24.9%33.7%

Return vs Industry: AGTC underperformed the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: AGTC underperformed the US Market which returned 30.7% over the past year.

Price Volatility

Is AGTC's price volatile compared to industry and market?
AGTC volatility
AGTC Beta2.15
Industry Beta1.03
Market Beta1

Stable Share Price: AGTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: AGTC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199983Sue Washerhttps://www.agtc.com

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease.

Valuation

Is Applied Genetic Technologies undervalued compared to its fair value and its price relative to the market?

1.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGTC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGTC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGTC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AGTC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGTC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGTC is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.1x).


Future Growth

How is Applied Genetic Technologies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

12.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGTC's revenue (67.2% per year) is forecast to grow faster than the US market (9.5% per year).

High Growth Revenue: AGTC's revenue (67.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGTC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Applied Genetic Technologies performed over the past 5 years?

-57.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGTC is currently unprofitable.

Growing Profit Margin: AGTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 57% per year.

Accelerating Growth: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: AGTC has a negative Return on Equity (-62.06%), as it is currently unprofitable.


Financial Health

How is Applied Genetic Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: AGTC's short term assets ($113.0M) exceed its short term liabilities ($16.6M).

Long Term Liabilities: AGTC's short term assets ($113.0M) exceed its long term liabilities ($16.1M).


Debt to Equity History and Analysis

Debt Level: AGTC's debt to equity ratio (10.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AGTC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGTC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AGTC has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 35.5% each year.


Dividend

What is Applied Genetic Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGTC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

17.5yrs

Average management tenure


CEO

Sue Washer (60 yo)

19.5yrs

Tenure

US$988,253

Compensation

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...


CEO Compensation Analysis

Compensation vs Market: Sue's total compensation ($USD988.25K) is above average for companies of similar size in the US market ($USD545.00K).

Compensation vs Earnings: Sue's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AGTC's management team is seasoned and experienced (17.5 years average tenure).


Board Members

Experienced Board: AGTC's board of directors are considered experienced (8.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 65.8%.


Top Shareholders

Company Information

Applied Genetic Technologies Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Applied Genetic Technologies Corporation
  • Ticker: AGTC
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$139.381m
  • Shares outstanding: 42.75m
  • Website: https://www.agtc.com

Number of Employees


Location

  • Applied Genetic Technologies Corporation
  • 14193 NW 119th Terrace
  • Suite 10
  • Alachua
  • Florida
  • 32615
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 04:32
End of Day Share Price2021/09/15 00:00
Earnings2021/03/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.